Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Tech medical study

Pediatric GLP-1 Nutritional Deficiency Study

Analysis based on 9 articles · First reported Sep 21, 2026 · Last updated Sep 24, 2026

Sentiment
-10
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The study could pressure GLP-1 manufacturers Novo Nordisk and Eli Lilly and Company by highlighting safety concerns and potential regulatory scrutiny over pediatric prescribing, though the observational nature limits immediate market disruption. It may also boost demand for nutritional supplements and counseling services, benefiting companies like FrieslandCampina — FrieslandCampina WAMCO and Roquette Frères that supply complementary nutrition solutions.

pharmaceuticals healthcare nutrition

A study published in the journal Childhood Obesity found that nearly one in six children and teenagers (16.8%) prescribed GLP-1 medications for weight loss, prediabetes, or type 2 diabetes were diagnosed with a nutritional deficiency within their first year of treatment. The research, led by senior author Justin Ryder of Lurie Children s Hospital and Northwestern University, analyzed national administrative claims data from 2017 to 2022 covering over 100 million patients, identifying 2,031 GLP-1 users aged 10 to 17. Vitamin D deficiency was the most common diagnosis at 12.4%, followed by nutritional anemia at 1.55% and iron-deficiency anemia at 1.44%. The most prescribed GLP-1s in the sample were liraglutide (78.6%), dulaglutide (10.4%), and semaglutide (9.1%). Researchers found that only about 5% of patients received nutritional counseling within 30 days of starting treatment and less than 25% within six months. The study is observational and shows association rather than causation. The American Academy of Pediatrics began recommending GLP-1 therapy for childhood obesity in 2023, emphasizing nutritional support. The findings add to growing research on GLP-1 risks and could influence prescribing practices and monitoring guidelines for pediatric patients.

85 Justin Ryder published study
70 Lurie Children s Hospital released study findings
40 American Academy of Pediatrics recommended GLP-1 therapy
per
As senior author, he is the lead voice calling for proactive nutritional management and monitoring for children on GLP-1 medications.
Importance 75.0 Sentiment 5.0
priv
The hospital led the study and its researchers authored the findings, positioning it as a key source of pediatric GLP-1 safety research.
Importance 70.0 Sentiment 5.0
stock
As maker of semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda), the company faces potential reputational and regulatory pressure from findings on pediatric nutritional deficiencies.
Importance 60.0 Sentiment -15.0
stock
As maker of tirzepatide (Mounjaro, Zepbound) and dulaglutide (Trulicity), the company could see increased scrutiny over pediatric use and monitoring requirements.
Importance 55.0 Sentiment -10.0
ngo
Its 2023 recommendation of GLP-1 therapy for childhood obesity emphasized nutritional support, and the study suggests real-world practice often falls short of that guidance.
Importance 45.0 Sentiment 0.0
govactor
The agency approved semaglutide for adolescents aged 12 to 17, and the study's findings may inform future labeling or monitoring guidance.
Importance 40.0 Sentiment 0.0
govactor
The agency's data on childhood obesity rates provides context for the growing pediatric GLP-1 market and the public health stakes.
Importance 25.0 Sentiment 0.0
subs
The ingredients supplier could benefit from increased demand for complementary nutritional solutions for GLP-1 users.
Importance 15.0 Sentiment 10.0
priv
The ingredient company may see opportunities in formulating nutritional products targeting GLP-1 users with deficiencies.
Importance 15.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.